RALEIGH–BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a commercial stage specialty pharmaceutical company focused on treatments for patients living with chronic pain, reported a third quarter loss of ten cents per share versus the Zacks Consensus Estimate of a loss of $14 cents.
This compares to loss of 21 cents per share a year ago. These figures are adjusted for non-recurring items.
Biodelivery reported record financial results but missed analysts estimates. It posted revenues of $14.16 million for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.38 percent. This compares to year-ago revenues of $11.25 million.
The company achieved strong BELBUCA revenue performance with sales increasing to $12.4 million, up 92 percent year-over-year and 27 percent versus prior quarter.
BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence.
BioDelivery shares have added about 27.8 percent since the beginning of the year versus the S&P 500’s gain of 5.3 percent.
Biodelivery shares traded at a stable $3.60 Friday afternoon.
